MARKET

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.61
+0.09
+0.86%
Pre Market: 11.00 +0.39 +3.68% 07:46 07/09 EDT
OPEN
10.60
PREV CLOSE
10.52
HIGH
10.81
LOW
10.34
VOLUME
1.73M
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
4.810
MARKET CAP
1.49B
P/E (TTM)
-12.7647
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SGMO stock price target is 20.43 with a high estimate of 36.00 and a low estimate of 11.00.

EPS

SGMO News

More
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of
Benzinga · 06/24 12:11
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Business Wire · 06/24 12:00
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $14
HC Wainwright & Co. maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and lowers the price target from $16 to $14.
Benzinga · 06/22 10:51
Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)
Insider Monkey · 06/19 17:22
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
Reuters · 06/18 14:44
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Business Wire · 06/18 14:00
Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial
MotleyFool.com · 06/18 04:00
Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?
Zacks · 06/16 13:36

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About SGMO

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
More

Webull offers kinds of Sangamo Therapeutics Inc stock information, including NASDAQ:SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.